Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLK3 | P49761 | 18/20 | 0.71 |
| ▸ | DYRK1A | Q13627 | 18/20 | 0.71 |
| ▸ | CLK2 | P49760 | 17/20 | 0.71 |
| ▸ | CLK1 | P49759 | 1/20 | 0.55 |
| ▸ | GSK3B | P49841 | 1/20 | 0.55 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.55 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.55 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.55 |
| ▸ | WNT1 | P04628 | 3/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18448012 | 0.94 | CLK2 (0.80) | CLK3DYRK1ACLK2CLK1GSK3B | |
| SCHEMBL18447438 | 0.89 | CLK2 (0.72) | CLK3DYRK1ACLK2CLK1GSK3B | |
| SCHEMBL18448798 | 0.85 | CLK2 (0.73) | CLK3DYRK1ACLK2WNT1 | |
| SCHEMBL20452287 | 0.85 | CLK2 (0.84) | CLK3DYRK1ACLK2WNT1 | |
| SCHEMBL18452608 | 0.85 | CLK2 (0.66) | CLK3DYRK1ACLK2CLK1GSK3B | |
| SCHEMBL18448070 | 0.85 | CLK2 (0.80) | CLK3DYRK1ACLK2WNT1 | |
| SCHEMBL18442438 | 0.84 | CLK2 (0.67) | CLK3DYRK1ACLK2WNT1 | |
| SCHEMBL20454708 | 0.84 | CLK2 (0.82) | CLK3DYRK1ACLK2WNT1 | |
| SCHEMBL18448306 | 0.84 | CLK2 (0.78) | CLK3DYRK1ACLK2WNT1 | |
| SCHEMBL18441275 | 0.84 | CLK2 (0.70) | CLK3DYRK1ACLK2WNT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017024013-A1 | 3-(1H-PYRROLO[2,3-C]PYRIDIN-2-YL)-1H-INDAZOLES AND THERAPEUTIC USES THEREOF | SAMUMED, LLC. (US) | 2017-02-09 | — | — | WO | disclosed |